Log in Free sign up

Eiger BioPharmaceuticals (EIGR) News and press releases

News

From Benzinga Pro

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine

Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Eiger Biopharmaceuticals And AnGes Announce Exclusive Partnership For Regulatory Approval And Commercialization Of Zokinvy In Japan

News, Contracts

Eiger Biopharmaceuticals Inc. ((", Eiger", , NASDAQ:EIGR) and AnGes Inc. ((", AnGes", , TYO:4563) today announced that the companies entered into an agreement for the regulatory approval, marketing,

Eiger BioPharmaceuticals Q1 EPS $(0.64), Inline, Sales $2.67M Miss $4.04M Estimate

Eiger BioPharmaceuticals (NASDAQ:EIGR) reported quarterly losses of $(0.64) per share which met the analyst consensus estimate. This is a 175.29 percent decrease over earnings of $0.85 per share from the same period last

Earnings Scheduled For May 5, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

Eiger Biopharmaceuticals Gramted U.S. Patent #11,311,519 Treatment of hepatitis delta virus infection

View patent here

Eiger Announces Publication Of Phase 2 Results Of Avexitide In Children With Congenital Hyperinsulinism And Initiation Of Phase 3 Program

Biotech, General

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases,

64 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co.

31 Stocks Moving In Thursday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers TD Holdings, Inc. (NASDAQ: GLG) rose 83.2% to $0.4348 after the company reported FY21 results.

Mid-Morning Market Update: Markets Edge higher; US Weekly Jobless Claims Drop To 214,000

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded slightly higher this morning following the release of weekly jobless claims data on Thursday.

Why Eiger BioPharmaceuticals Stock Is Jumping Today

Biotech, News, Health Care, Movers, Trading Ideas, General

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to severe illness.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Eiger BioPharma Reports Single Dose Of Its Lambda For COVID 'significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits greater than six hours by 50%'

Biotech, News, FDA, General

Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Eiger BioPharmaceuticals's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, Eiger BioPharmaceuticals's (NASDAQ:EIGR) reported sales totaled $3.36 million. Despite a 2.05% increase in earnings, the company posted a loss of $21.77 million.

95 Biggest Movers From Friday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9.51.

Eiger BioPharmaceuticals: Q4 Earnings Insights

Eiger BioPharmaceuticals (NASDAQ:EIGR) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Eiger BioPharmaceuticals reported in-line EPS of $-0.64 versus an estimate of $-0.64.

Eiger BioPharmaceuticals Q4 EPS $(0.64), Inline

Eiger BioPharmaceuticals (NASDAQ:EIGR) reported quarterly losses of $(0.64) per share which met the analyst consensus estimate. This is a 10.34 percent decrease over losses of $(0.58) per share from the same period last

Earnings Scheduled For March 10, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million.

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg

Biotech, Earnings, News, Penny Stocks, Small Cap, Top Stories, General

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.

Press releases

From Benzinga Pro

Eiger BioPharmaceuticals to Present at H.C. Wainwright Global Investment Conference

PALO ALTO, Calif, May 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis

Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan

PALO ALTO, Calif. and OSAKA, Japan, May 10, 2022 /PRNewswire/ -- Eiger Biopharmaceuticals Inc. ((", Eiger", , NASDAQ:EIGR) and AnGes Inc. ((", AnGes", , TYO:4563) today announced that the companies entered

Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Earnings, Press Releases

Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year EndZokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022Phase 3

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PALO ALTO, Calif., April 29, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis

Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program

- Phase 2 study demonstrating avexitide significantly reduced hypoglycemia in children with congenital hyperinsulinism published in Diabetes Care- Eiger plans to initiate avexitide Phase 3 registrational program by

Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5

- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development

Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments

Chris Kurtz Appointed Chief Technical OfficerSarah Mathieson Appointed Senior Vice President, Corporate AffairsPALO ALTO, Calif., April 18, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a

Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study

Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related death Primary

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022

Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Earnings, Press Releases

PALO ALTO, Calif., March 10, 2022 /PRNewswire/ -- Phase 3 COVID-19 TOGETHER (Lambda) Study Data in

Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10

PALO ALTO, Calif., Feb. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis